WCLC: With Keytruda-Yervoy data, Merck casts doubt on Opdivo's place in lung cancer

Bristol Myers Squibb just broke into previously untreated non-small cell lung cancer less than a year ago with an FDA go-ahead in PD-L1-positive patients for the dual checkpoint inhibitor regimen of Opdivo and Yervoy. But rival Merck & Co. is already casting doubt on its place in the lucrative market.